Advertisement
Screener

Perrigo Company plc (PRGO) Scorecard

2.8 / 5 stars · 68/120 Roast Me

Perrigo Company plc (PRGO) Scorecard

  • 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Win.
  • 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Win.
  • 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Win.
  • 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
28/120 All 120 Win/Lose results shown below

Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.

Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026

Complete point ledger

Each cell identifies the missing side explicitly.

QuarterTotal returnRevenue growthEPS growth
2026-Q21/3 LosePRGO / S&P
-0.74% / 15.20%
LosePRGO / S&P
-4.19% / 15.00%
WinPRGO / S&P
2060.34% / 50.40%
2026-Q11/3 LosePRGO / S&P
-21.11% / -4.33%
LosePRGO / S&P
-3.62% / 11.30%
WinPRGO / S&P
901.53% / 27.70%
2025-Q41/3 LosePRGO / S&P
-37.49% / 2.65%
LosePRGO / S&P
-2.75% / 9.00%
WinPRGO / S&P
724.00% / 13.40%
2025-Q30/3 LosePRGO / S&P
-15.62% / 8.12%
LosePRGO / S&P
-2.51% / 4.61%
LosePRGO / S&P
-67.24% / 13.45%
2025-Q20/3 LosePRGO / S&P
-3.68% / 10.94%
LosePRGO / S&P
-2.31% / 4.83%
LosePRGO / S&P
-36.26% / 10.63%
2025-Q12/3 WinPRGO / S&P
10.18% / -4.27%
LosePRGO / S&P
-4.84% / 4.98%
WinPRGO / S&P
2083.33% / 10.57%
2024-Q41/3 LosePRGO / S&P
-1.04% / 2.41%
LosePRGO / S&P
-6.06% / 5.25%
WinPRGO / S&P
1288.89% / 6.15%
2024-Q31/3 LosePRGO / S&P
3.12% / 5.89%
LosePRGO / S&P
-5.63% / 5.89%
WinPRGO / S&P
3766.67% / 6.11%
2024-Q21/3 LosePRGO / S&P
-19.42% / 4.28%
LosePRGO / S&P
-4.36% / 5.38%
WinPRGO / S&P
82.00% / 5.12%
2024-Q10/3 LosePRGO / S&P
1.02% / 10.56%
LosePRGO / S&P
-0.07% / 5.71%
LosePRGO / S&P
-94.23% / 5.59%
2023-Q40/3 LosePRGO / S&P
1.63% / 11.69%
LosePRGO / S&P
4.58% / 6.81%
LosePRGO / S&P
-91.35% / 7.78%
2023-Q30/3 LosePRGO / S&P
-5.17% / -3.27%
LosePRGO / S&P
5.74% / 7.52%
LosePRGO / S&P
-96.25% / -5.03%
2023-Q20/3 LosePRGO / S&P
-4.54% / 8.74%
LosePRGO / S&P
6.60% / 9.50%
LosePRGO / S&P
-42.53% / -8.57%
2023-Q11/3 LosePRGO / S&P
6.00% / 7.50%
LosePRGO / S&P
8.46% / 10.77%
WinPRGO / S&P
26.83% / -15.69%
2022-Q41/3 LosePRGO / S&P
-3.63% / 7.56%
LosePRGO / S&P
7.56% / 11.88%
WinPRGO / S&P
100.00% / -17.99%
2022-Q30/3 LosePRGO / S&P
-11.49% / -4.88%
LosePRGO / S&P
7.69% / 13.47%
LosePRGO / S&P
-57.22% / -1.41%
2022-Q21/3 WinPRGO / S&P
6.26% / -16.10%
LosePRGO / S&P
7.33% / 13.71%
LosePRGO / S&P
-65.88% / 11.04%
2022-Q11/3 WinPRGO / S&P
-0.47% / -4.60%
LosePRGO / S&P
4.69% / 15.97%
LosePRGO / S&P
-51.19% / 42.23%
2021-Q40/3 LosePRGO / S&P
-17.26% / 11.03%
LosePRGO / S&P
1.23% / 15.00%
LosePRGO / S&P
-56.30% / 96.40%
2021-Q33/3 WinPRGO / S&P
3.84% / 0.58%
WinPRGO / S&P
20.55% / 10.77%
WinPRGO / S&P
3640.00% / 69.42%
2021-Q22/3 WinPRGO / S&P
13.87% / 8.55%
WinPRGO / S&P
13.10% / 6.58%
LosePRGO / S&P
-246.55% / 51.81%
2021-Q11/3 LosePRGO / S&P
-8.98% / 6.17%
WinPRGO / S&P
6.25% / -1.06%
LosePRGO / S&P
-222.63% / 7.39%
2020-Q41/3 LosePRGO / S&P
-2.14% / 12.15%
WinPRGO / S&P
5.64% / -3.72%
LosePRGO / S&P
-211.21% / -33.42%
2020-Q30/3 LosePRGO / S&P
-16.58% / 8.93%
LosePRGO / S&P
-28.01% / -2.04%
LosePRGO / S&P
-102.78% / -27.10%
2020-Q21/3 LosePRGO / S&P
15.40% / 20.54%
LosePRGO / S&P
-23.07% / -0.46%
WinPRGO / S&P
171.88% / -27.11%
2020-Q12/3 WinPRGO / S&P
-6.56% / -19.60%
LosePRGO / S&P
-19.42% / 3.47%
WinPRGO / S&P
65.06% / -14.75%
2019-Q41/3 LosePRGO / S&P
-7.18% / 9.07%
LosePRGO / S&P
-18.21% / 5.36%
WinPRGO / S&P
15.05% / 2.99%
2019-Q32/3 WinPRGO / S&P
17.90% / 1.70%
LosePRGO / S&P
-2.28% / 5.02%
WinPRGO / S&P
109.30% / 0.21%
2019-Q20/3 LosePRGO / S&P
-0.66% / 4.30%
LosePRGO / S&P
-5.41% / 6.64%
LosePRGO / S&P
-61.45% / 8.65%
2019-Q11/3 WinPRGO / S&P
24.79% / 13.65%
LosePRGO / S&P
-5.64% / 8.12%
LosePRGO / S&P
-8.79% / 14.29%
2018-Q40/3 LosePRGO / S&P
-45.10% / -13.52%
LosePRGO / S&P
-4.34% / 9.05%
LosePRGO / S&P
10.71% / 18.23%
2018-Q30/3 LosePRGO / S&P
-2.65% / 7.71%
LosePRGO / S&P
-3.50% / 10.21%
LosePRGO / S&P
-109.39% / 19.06%
2018-Q20/3 LosePRGO / S&P
-12.30% / 3.43%
LosePRGO / S&P
-2.13% / 9.03%
LosePRGO / S&P
-108.07% / 14.46%
2018-Q10/3 LosePRGO / S&P
-4.16% / -0.76%
LosePRGO / S&P
-3.08% / 7.68%
LosePRGO / S&P
-103.82% / 12.46%
2017-Q40/3 LosePRGO / S&P
3.15% / 6.64%
LosePRGO / S&P
-6.33% / 7.03%
LosePRGO / S&P
-103.00% / 13.82%
2017-Q31/3 WinPRGO / S&P
12.32% / 4.48%
LosePRGO / S&P
PRGO unavailable / 5.68%
LosePRGO / S&P
PRGO unavailable / 17.57%
2017-Q21/3 WinPRGO / S&P
14.00% / 3.09%
LosePRGO / S&P
PRGO unavailable / 4.83%
LosePRGO / S&P
PRGO unavailable / 17.74%
2017-Q10/3 LosePRGO / S&P
-20.06% / 6.07%
LosePRGO / S&P
PRGO unavailable / 3.67%
LosePRGO / S&P
PRGO unavailable / 13.32%
2016-Q40/3 LosePRGO / S&P
-9.71% / 3.82%
LosePRGO / S&P
PRGO unavailable / 2.09%
LosePRGO / S&P
PRGO unavailable / 7.05%
2016-Q30/3 LosePRGO / S&P
1.99% / 3.85%
LosePRGO / S&P
PRGO unavailable / 0.20%
LosePRGO / S&P
PRGO unavailable / -3.15%

Dividend-reinvested, split-adjusted total return

1Y · 2025-08-29 to 2026-08-27

MetricPRGO total returnS&P 500 Total Return Index
Total return-36.50%20.78%
Annualized return-36.50%20.78%

5Y · 2021-09-01 to 2026-08-27

MetricPRGO total returnS&P 500 Total Return Index
Total return-57.20%83.14%
Annualized return-15.61%12.86%

10Y · 2016-09-01 to 2026-08-27

MetricPRGO total returnS&P 500 Total Return Index
Total return-79.58%319.30%
Annualized return-14.69%15.41%

Calculation rules

window
Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
return Basis
Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
point Rule
Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
frequency
Quarter endpoints only.
fundamentals
Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
non Scoring

Snapshot captured 2026-09-04.

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05
Generate Biomedicines, Inc. (GENB)United States$2.052B
UroGen Pharma Ltd. (URGN)$2.015B-18.42
Nuvation Bio Inc. (NUVB)United States$2.007B-13.12
Biohaven Ltd. (BHVN)United States$1.990B-3.83
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Braveheart Bio, Inc. (BRVE)United States$2.106B
Bausch Health Companies Inc. (BHC)$2.113B-1.68
AGIOS PHARMACEUTICALS, INC. (AGIO)United States$1.962B-5.38